LQDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Liquidia Corp (LQDA) is not an ideal buy for a beginner investor with a long-term focus at this moment. While the company shows strong revenue growth and bullish technical indicators, insider selling, mixed analyst ratings, and concerns raised by executive stock sales suggest caution. The lack of strong proprietary trading signals further supports a hold recommendation.
The technical indicators are bullish with a positively expanding MACD, RSI in the neutral zone, and moving averages showing an upward trend (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 41.212) in the pre-market, with a pre-market price of 41.6.
Strong revenue growth in Q4 2025 (up 3054.65% YoY).
Bullish technical indicators.
Analysts from Wells Fargo and H.C. Wainwright raised price targets significantly, indicating confidence in the company's competitive positioning in the pulmonary hypertension market.
Significant insider selling by the CEO and CFO, raising concerns about the company's outlook.
Net income and EPS dropped significantly YoY in Q4
Oppenheimer maintains an Underperform rating, citing concerns about product differentiation.
Hedge funds remain neutral, and there are no significant trading trends.
In Q4 2025, revenue increased significantly to $92.02M (up 3054.65% YoY), but net income dropped to $14.55M (-140.13% YoY), and EPS fell to 0.17 (-139.53% YoY). Gross margin improved to 92.33% (up 72.32% YoY).
Mixed ratings: Wells Fargo and H.C. Wainwright are bullish, with price targets raised to $51 and $55, respectively. However, Oppenheimer remains bearish with an Underperform rating and a price target of $19, citing concerns about product differentiation.
